FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
The FDA has approved Moderna’s messenger RNA (mRNA) seasonal influenza vaccine, mFLUSIVA (mRNA-1010), for the prevention of seasonal influenza in…
Analyst Comment
Beyond memory: could changes in movement and the senses detect dementia earlier?
D&D Pharmatechs’ zabopegdutide shows rapid, weight-loss-independent MASH benefit
China’s rapid rise in drug development casts a long shadow over US oncology
US dominates Alzheimer’s disease studies
Minimum age threshold introduced for puberty blocker clinical trial
European scientists advocate for integrative approach to obesity prevention
MASH therapy enters a more competitive era
